Central European Journal of Medicine

, Volume 3, Issue 2, pp 199–202 | Cite as

IL-2, IL-6 and IL-8 levels remain unaltered in the course of immunosuppressive therapy after renal transplantation

  • Jacek Rysz
  • Eugeniusz Kocur
  • Robert Blaszczak
  • Piotr Bartnicki
  • Robert A. Stolarek
  • Mariusz Piechota
Research Article


Cytokines regulate the immune reactions elicited by renal transplantation (RT). This study was designed to investigate the blood serum levels of IL-2, IL-6, IL-8 in 25 RT patients (10 female and 15 male, mean 5.4±2.7 yrs after RT) three times over a six-month period during standard immunosuppressive therapy with cyclosporine A, azathioprine and prednisolone. The levels of IL-2, IL-6 and IL-8 were tested with ELISA Quantikine Human Interleukin Immunoassay (R&D Systems, detection level 7,0.7 and 10 pg/cm3, respectively). There was no significant alternation of blood serum levels of IL-2, IL-6 and IL-8 in the study patients.


Cytokines Lymphocytes Transplantation Immune system 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Whicher J.T., Evans S.W., Cytokines in disease, Clin. Chem., 1990, 36, 1269–1281PubMedGoogle Scholar
  2. [2]
    Rysz J., Banach M., Ciałkowska-Rysz A., Stolarek R., Drozdz J., Okoński P., Blood serum levels of IL-2, IL-6, IL-8, TNF-a and IL-1b in patients on maintenance hemodialysis, Cell. Mol. Immunol., 2006, 3, 151–154PubMedGoogle Scholar
  3. [3]
    Descamps-Latscha B., Herbelin A., Nguyen A.T., Roux-Lombard P., Zingraff J., Moynot A., et al., Balance between IL-1b, TNF-a, and their specific inhibitors in chronic renal failure and maintenance dialysis, J. Immunol., 1995, 154, 882–892PubMedGoogle Scholar
  4. [4]
    Bock G.H., Neu L., Long C., Patterson L.T., Korb S., Gelpi J., et al., Assessment of serum and urine soluble interleukin-2 receptor concentration during renal transplant rejection, Am. J. Kidney Dis., 1994, 23, 421–426PubMedGoogle Scholar
  5. [5]
    Dobbelstein H., Immune system in uremia, Nephron, 1976, 17, 409–414PubMedGoogle Scholar
  6. [6]
    Kang X., Hirano T., Oka K., Tamak T., Samurai E., Kaji N., et al., Recovery of decreased ability of peripheral-blood mononuclear cells from chronic renal failure to produce interleukin-1 after renal transplantation. Nephron, 1991, 58, 450–455PubMedCrossRefGoogle Scholar
  7. [7]
    Rysz J., Stolarek R.A., Majewska E., Banach M., Cialkowska-Rysz A., Baj Z., The increased levels of soluble TNFa receptors and cellular adhesion molecules in patients undergoing bioincompatible hemodialysis, Am. J. Nephrol., 2006, 26, 437–444PubMedCrossRefGoogle Scholar
  8. [8]
    Allegre M.L., Costimulatory molecules as targets for the induction of transplantation tolerance, Nephrol. Dial. Transplant., 1999, 14, 322–332CrossRefGoogle Scholar
  9. [9]
    Jakóbisiak M.,Immunologia. Wydawnictwo Naukowe PWN, Warszawa, Poland, 141–145, 478–524, 1993Google Scholar
  10. [10]
    Schwarz C., Oberbauer R., The influence of organ donor factors on early allograft function, Curr. Opin. Urol., 2003, 13, 99–104PubMedCrossRefGoogle Scholar
  11. [11]
    Hermelin A., Urena P., Nguyen A.T., Zingraff J., Descamps-Latscha B., Elevated circulating levels of interleukin-6 in patients with chronic failure, Kidney Int., 1991, 39, 954–960CrossRefGoogle Scholar
  12. [12]
    Kutuckuler N., Clark K., Rigg K.M., The value of posttransplant monitoring of IL-2, IL-3, IL-4, IL-6, IL-8 and soluble CD23 in the plasma of renal allograft recipients, Transplantation, 1995, 59, 333–337Google Scholar
  13. [13]
    Budde K., Waiser J., Ceska J., Katalinic A., Kürzdörfer M., Neumayer H.H., Interleukin-8 expression in patients after renal transplantation, Am. J. Kidney Dis., 1997, 29, 871–875PubMedCrossRefGoogle Scholar
  14. [14]
    Boratynska M., Urine and serum levels of interleukin-8 in patients after renal transplantation, Przegl. Lek. 1998, 55, 576–580PubMedGoogle Scholar
  15. [15]
    Waiser J., Budde K., Katalinic A., Kuerzdörfer M., Riess R., Neumayer H.H., Interleukin-6 expression after renal transplantation. Nephrol. Dial. Transplant., 1997, 12, 753–759PubMedCrossRefGoogle Scholar
  16. [16]
    Noronha I., Niemir Z., Stein H., Waldherr R., Cytokines and growth factors in renal disease, Nephrol. Dial. Transplant., 1995, 10, 775–786PubMedGoogle Scholar
  17. [17]
    Bachórzewska-Gajewska H., Małyszko J., Sitniewska E., Małyszko J., Dobrzycki S., Prevention of contrast-induced nephropathy in patients undergoing percutaneous coronary interventions in everyday clinical practice, Arch. Med. Sci., 2006, 2, 256–261Google Scholar
  18. [18]
    Rysz J., Stolarek R., Banach M., Pasnik J., Okoński P., Baj Z., et al. TNF-alfa priming effect on polymorphonuclear leukocytes reactive species generation and adhesion molecule expression in hemodialyzed patients, Arch. Immunol. Ther. Exp., 2006, 54, 209–215CrossRefGoogle Scholar
  19. [19]
    Rysz J., Kocur E., Błaszczak R., Stolarek R., Integrin CD11a/CD18, CD11b/CD18 and CD69 expression in patients after renal transplantation, Cent. Eur. J. Med., 2007, 2, 154–158CrossRefGoogle Scholar

Copyright information

© © Versita Warsaw and Springer-Verlag Berlin Heidelberg 2008

Authors and Affiliations

  • Jacek Rysz
    • 1
  • Eugeniusz Kocur
    • 1
  • Robert Blaszczak
    • 1
  • Piotr Bartnicki
    • 1
  • Robert A. Stolarek
    • 2
  • Mariusz Piechota
    • 3
  1. 1.2nd Department of Family MedicineMedical University of LodzLodzPoland
  2. 2.Department of Experimental and Clinical PhysiologyMedical University of LodzLodzPoland
  3. 3.Department of Anaesthesiology and Intensive Care UnitUniversity Hospital No. 5 in Lodz, Medical University of LodzLodzPoland

Personalised recommendations